TrialActa dermato-venereologica2026

Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.

Diamant Thaçi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.